Antiviral Host Defense Enhancers
Minimising the Impact of Viral Respiratory Infections
ENA Respiratory is a clinical-stage pharmaceutical company developing antiviral host defense enhancers for the prevention of severe in at-risk populations.
INNA-051
Novel, virus-agnostic mode of action
The company’s lead product is INNA-051, a first-in-class TLR2/6 agonist developed as a convenient, self-administered nasal product with a weekly dosing regimen.
INNA-051 works by priming and boosting the body’s natural first line of defence at the primary entry site of viral respiratory infections in the upper respiratory tract. This leads to accelerated viral clearance and reduced virus dissemination to the lower airways (lungs).
Team
Working to deliver for at-risk populations
INNA-051 clinical development is led by an experienced team of clinicians and drug developers who have a deep understanding of respiratory diseases and a track record of bringing multiple new respiratory treatments to the US and other markets.
We are focused on improving the lives of vulnerable populations at risk of complications from respiratory viral infections and minimising the burden on the health care system.
INNA-051 is effective against multiple respiratory viruses and has demonstrated a favourable safety profile that supports seasonal prophylactic use and a fast onset of action with a durable response to enable weekly dosing.
Latest News
ENA Respiratory Partners with University of Maryland and Leading Respiratory Disease Expert to Conduct Phase 2 Study of INNA-051 Antiviral Host Defence Enhancer
ENA Respiratory Announces Publication Supporting the Potential of its Novel Intranasal Therapy INNA-051 to Reduce the Impact of Viral Respiratory Infections in Older Adults